Surface-associated plasminogen binding of Cryptococcus neoformans promotes extracellular matrix invasion

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Stie, Jamal ^a   Bruni, Gillian ^c   Fox, Deborah ^a,b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANE PROTEIN; FUNGAL PROTEIN; PLASMINOGEN; COLLAGEN; FIBRIN;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; CELL INVASION; CELL MEMBRANE PERMEABILITY; CELL SURFACE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FUNCTIONAL PROTEOMICS; FUNGAL VIRULENCE; NONHUMAN; PERMEABILITY BARRIER; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; AMINO ACID SEQUENCE; BRAIN; CELL WALL; CENTRAL NERVOUS SYSTEM; CHEMISTRY; FIBRINOLYSIS; HUMAN; LUNG; MENINGOENCEPHALITIS; METABOLISM; METHODOLOGY; MICROBIOLOGY; MOLECULAR GENETICS; PATHOLOGY; PROTEOMICS; SURFACE PROPERTY;

FILOBASIDIELLA NEOFORMANS;

AMINO ACID SEQUENCE; BRAIN; CELL WALL; CENTRAL NERVOUS SYSTEM; COLLAGEN; CRYPTOCOCCUS NEOFORMANS; EXTRACELLULAR MATRIX; FIBRIN; FIBRINOLYSIS; HUMANS; LUNG; MENINGOENCEPHALITIS; MOLECULAR SEQUENCE DATA; PLASMINOGEN; PROTEOMICS; SURFACE PROPERTIES;

EID: 66749148271     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005780     Document Type: Article

References (89)

1. Chang YC, Stins MF, McCaffery MJ, Miller GF, Pare DR, et al. (2004) Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect Immun 72(9): 4985-4995.
2. Charlier C, Chretien F, Baudrimont M, Mordelet E, Lortholary O, et al. (2005) Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol 166(2): 421-432.
3. Chen SH, Stins MF, Huang SH, Chen YH, Kwon-Chung KJ, et al. (2003) Cryptococcus neoformans induces alterations in the cytoskeleton of human brain microvascular endothelial cells. J Med Microbiol 52(Pt 11): 961-970.
4. Chretien F, Lortholary O, Kansau I, Neuville S, Gray F, et al. (2002) Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis 186(4): 522-530.
5. Huang SH, Jong AY (2001) Cellular mechanisms of microbial proteins contributing to invasion of the blood-brain barrier. Cell Microbiol 3(5): 277-287.
6. Hadley S, Karchmer AW (1995) Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 9(4): 1045-1074.
7. Liu ZY, Sheng RY, Li XL, Li TS, Wang AX (2003) Nosocomial fungal infections, analysis of 149 cases. Zhonghua Yi Xue Za Zhi 83(5): 399-402.
8. Perfect JR, Durack DT, Gallis HA (1983) Cryptococcemia. Medicine (Baltimore) 62(2): 98-109.
9. Santos J, Palacios R, Esteve A, Garcia V, Rivero A, et al. (1998) Fungemia in patients with HIV infection. An Med Interna 15(10): 523-527.
10. St Georgiev V (1993) Opportunistic/nosocomial infections. Treatment and developmental therapeutics. I. Cryptococcosis. Med Res Rev 13(4): 493-506.
11. Walsh TJ, Groll AH (1999) Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis 1(4): 247-261.
12. Wang CY, Wu HD, Hsueh PR (2005) Nosocomial transmission of cryptococcosis. N Engl J Med 352(12): 1271-1272.
13. Chin CS, Cheong YM, Wong YH (1989) 5-Fluorocytosine resistance in clinical isolates of Cryptococcus neoformans. Med J Malaysia 44(3): 194-198.
14. Maligie MA, Selitrennikoff CP (2005) Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother 49(7): 2851-2856.
15. Perfect JR, Cox GM (1999) Drug resistance in Cryptococcus neoformans. Drug Resist Updat 2(4): 259-269.
16. Sar B, Monchy D, Vann M, Keo C, Sarthou JL, et al. (2004) Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother 54(2): 563-565.
17. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L, et al. (2001) Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107(5): E66.
18. Eisenman HC, Nosanchuk JD, Webber JB, Emerson RJ, Camesano TA, et al. (2005) Microstructure of cell wall-associated melanin in the human pathogenic fungus Cryptococcus neoformans. Biochemistry 44(10): 3683-3693.
19. Ikeda R, Sugita T, Jacobson ES, Shinoda T (2003) Effects of melanin upon susceptibility of Cryptococcus to antifungals. Microbiol Immunol 47(4): 271-277.
20. Reese AJ, Doering TL (2003) Cell wall alpha-1,3-glucan is required to anchor the Cryptococcus neoformans capsule. Mol Microbiol 50(4): 1401-1409.
21. van Duin D, Casadevall A, Nosanchuk JD (2002) Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother 46(11): 3394-3400.
22. Wang Y, Aisen P, Casadevall A (1995) Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun 63(8): 3131-3136.
23. Klis FM, Mol P, Hellingwerf K, Brul S (2002) Dynamics of cell wall structure in Saccharomyces cerevisiae. FEMS Microbiol Rev 26(3): 239-256.
24. Smits GJ, van den Ende H, Klis FM (2001) Differential regulation of cell wall biogenesis during growth and development in yeast. Microbiology 147(Pt 4): 781-794.
25. Chaffin WL, Lopez-Ribot JL, Casanova M, Gozalbo D, Martinez JP (1998) Cell wall and secreted proteins of Candida albicans: identification, function, and expression. Microbiol Mol Biol Rev 62(1): 130-180.
26. Kapteyn JC, Van Den Ende H, Klis FM (1999) The contribution of cell wall proteins to the organization of the yeast cell wall. Biochim Biophys Acta 1426(2): 373-383.
27. Poltermann S, Kunert A, von der Heide M, Eck R, Hartmann A, et al. (2007) Gpm1p is a factor H-, FHL-1-, and plasminogen-binding surface protein of Candida albicans. J Biol Chem 282(52): 37537-37544.
28. Huang C, Nong SH, Mansour MK, Specht CA, Levitz SM (2002) Purification and characterization of a second immunoreactive mannoprotein from Cryptococcus neoformans that stimulates T-Cell responses. Infect Immun 70(10): 5485-5493.
29. Mansour MK, Yauch LE, Rottman JB, Levitz SM (2004) Protective efficacy of antigenic fractions in mouse models of cryptococcosis. Infect Immun 72(3): 1746-1754.
30. Murphy JW, Mosley RL, Cherniak R, Reyes GH, Kozel TR, et al. (1988) Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens. Infect Immun 56(2): 424-431.
31. Orendi JM, Verheul AF, De Vos NM, Visser MR, Snippe H, et al. (1997) Mannoproteins of Cryptococcus neoformans induce proliferative response in human peripheral blood mononuclear cells (PBMC) and enhance HIV-1 replication. Clin Exp Immunol 107(2): 293-299.
32. Pietrella D, Cherniak R, Strappini C, Perito S, Mosci P, et al. (2001) Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans. Infect Immun 69(5): 2808-2814.
33. Pitzurra L, Vecchiarelli A, Peducci R, Cardinali A, Bistoni F (1997) Identification of a 105 kilodalton Cryptococcus neoformans mannoprotein involved in human cell-mediated immune response. J Med Vet Mycol 35(4): 299-303.
34. Vartivarian SE, Reyes GH, Jacobson ES, James PG, Cherniak R, et al. (1989) Localization of mannoprotein in Cryptococcus neoformans. J Bacteriol 171(12): 6850-6852.
35. Eigenheer RA, Jin Lee Y, Blumwald E, Phinney BS, Gelli A (2007) Extracellular glycosylphosphatidylinositol-anchored mannoproteins and proteases of Cryptococcus neoformans. FEMS Yeast Res 7(4): 499-510.
36. Rodrigues ML, dos Reis FC, Puccia R, Travassos LR, Alviano CS (2003) Cleavage of human fibronectin and other basement membrane-associated proteins by a Cryptococcus neoformans serine proteinase. Microb Pathog 34(2): 65-71.
37. Ponting CP, Marshall JM, Cederholm-Williams SA (1992) Plasminogen: a structural review. Blood Coagul Fibrinolysis 3(5): 605-614.
38. de Vos AM, Ultsch MH, Kelley RF, Padmanabhan K, Tulinsky A, et al. (1992) Crystal structure of the kringle 2 domain of tissue plasminogen activator at 2.4-A resolution. Biochemistry 31(1): 270-279.
39. Miles LA, Plow EF (1986) Topography of the high-affinity lysine binding site of plasminogen as defined with a specific antibody probe. Biochemistry 25(22): 6926-6933.
40. Novokhatny VV, Kudinov SA, Privalov PL (1984) Domains in human plasminogen. J Mol Biol 179(2): 215-232.
41. Lahteenmaki K, Edelman S, Korhonen TK (2005) Bacterial metastasis: the host plasminogen system in bacterial invasion. Trends Microbiol 13(2): 79-85.
42. Coleman JL, Benach JL (1999) Use of the plasminogen activation system by microorganisms. J Lab Clin Med 134(6): 567-576.
43. Barbosa MS, Bao SN, Andreotti PF, de Faria FP, Felipe MS, et al. (2006) Glyceraldehyde-3-phosphate dehydrogenase of Paracoccidioides brasiliensis is a cell surface protein involved in fungal adhesion to extracellular matrix proteins and interaction with cells. Infect Immun 74(1): 382-389.
44. Crowe JD, Sievwright IK, Auld GC, Moore NR, Gow NA, et al. (2003) Candida albicans binds human plasminogen: identification of eight plasminogen-binding proteins. Mol Microbiol 47(6): 1637-1651.
45. Fox D, Smulian AG (2001) Plasminogen-binding activity of enolase in the opportunistic pathogen Pneumocystis carinii. Med Mycol 39(6): 495-507.
46. Jong AY, Chen SH, Stins MF, Kim KS, Tuan TL, et al. (2003) Binding of Candida albicans enolase to plasmin(ogen) results in enhanced invasion of human brain microvascular endothelial cells. J Med Microbiol 52(Pt 8): 615-622.
47. Lahteenmaki K, Kuusela P, Korhonen TK (2000) Plasminogen activation in degradation and penetration of extracellular matrices and basement membranes by invasive bacteria. Methods 21(2): 125-132.
48. Zaas AK, Liao G, Chien JW, Weinberg C, Shore D, et al. (2008) Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet 4(6): e1000101.
49. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, et al. (1991) Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 30(6): 1682-1691.
50. Andronicos NM, Ranson M, Bognacki J, Baker MS (1997) The human ENO1 gene product (recombinant human alpha-enolase) displays characteristics required for a plasminogen binding protein. Biochim Biophys Acta 1337(1): 27-39.
51. Bergmann S, Rohde M, Chhatwal GS, Hammerschmidt S (2001) alpha-Enolase of Streptococcus pneumoniae is a plasmin(ogen)-binding protein displayed on the bacterial cell surface. Mol Microbiol 40(6): 1273-1287.
52. Bergmann S, Rohde M, Hammerschmidt S (2004) Glyceraldehyde-3-phosphate dehydrogenase of Streptococcus pneumoniae is a surface-displayed plasminogen-binding protein. Infect Immun 72(4): 2416-2419.
53. Coleman JL, Sellati TJ, Testa JE, Kew RR, Furie MB, et al. (1995) Borrelia burgdorferi binds plasminogen, resulting in enhanced penetration of endothelial monolayers. Infect Immun 63(7): 2478-2484.
54. de Groot PW, de Boer AD, Cunningham J, Dekker HL, de Jong L, et al. (2004) Proteomic analysis of Candida albicans cell walls reveals covalently bound carbohydrate-active enzymes and adhesins. Eukaryot Cell 3(4): 955-965.
55. Grab DJ, Perides G, Dumler JS, Kim KJ, Park J, et al. (2005) Borrelia burgdorferi, host-derived proteases, and the blood-brain barrier. Infect Immun 73(2): 1014-1022.
56. Litvintseva AP, Thakur R, Vilgalys R, Mitchell TG (2006) Multilocus sequence typing reveals three genetic subpopulations of Cryptococcus neoformans var. grubii (serotype A), including a unique population in Botswana. Genetics 172(4): 2223-2238.
57. Fox DS, Cruz MC, Sia RA, Ke H, Cox GM, et al. (2001) Calcineurin regulatory subunit is essential for virulence and mediates interactions with FKBP12-FK506 in Cryptococcus neoformans. Mol Microbiol 39(4): 835-849.
58. McDade HC, Cox GM (2001) A new dominant selectable marker for use in Cryptococcus neoformans. Med Mycol 39(1): 151-154.
59. Foster AJ, Bird RA, Smith SN (2007) Biotinylation and characterization of Cryptococcus neoformans cell surface proteins. J Appl Microbiol 103(2): 390-399.
60. Olson GM, Fox DS, Wang P, Alspaugh JA, Buchanan KL (2007) Role of protein O-mannosyltransferase Pmt4 in the morphogenesis and virulence of Cryptococcus neoformans. Eukaryot Cell 6(2): 222-234.
61. Pitarch A, Sanchez M, Nombela C, Gil C (2002) Sequential fractionation and two-dimensional gel analysis unravels the complexity of the dimorphic fungus Candida albicans cell wall proteome. Mol Cell Proteomics 1(12): 967-982.
62. Blum H, Beier H, Gross HJ (1987) Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels. Electrophoresis 8: 93-99.
63. Derbise A, Song YP, Parikh S, Fischetti VA, Pancholi V (2004) Role of the C-terminal lysine residues of streptococcal surface enolase in Glu- and Lysplasminogen-binding activities of group A streptococci. Infect Immun 72(1): 94-105.
64. Bryan RA, Zaragoza O, Zhang T, Ortiz G, Casadevall A, et al. (2005) Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans. Eukaryot Cell 4(2): 465-475.
65. Gates MA, Thorkildson P, Kozel TR (2004) Molecular architecture of the Cryptococcus neoformans capsule. Mol Microbiol 52(1): 13-24.
66. Loftus BJ, Fung E, Roncaglia P, Rowley D, Amedeo P, et al. (2005) The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science 307(5713): 1321-1324.
67. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL (1995) The cell biology of the plasminogen system. FASEB J 9(10): 939-945.
68. Kozel TR, Gotschlich EC (1982) The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol 129(4): 1675-1680.
69. Fromtling RA, Shadomy HJ, Jacobson ES (1982) Decreased virulence in stable, acapsular mutants of Cryptococcus neoformans. Mycopathologia 79(1): 23-29.
70. Bulmer GS, Sans MD, Gunn CM (1967) Cryptococcus neoformans. I. Nonencapsulated mutants. J Bacteriol 94(5): 1475-1479.
71. Kwon-Chung KJ, Rhodes JC (1986) Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun 51(1): 218-223.
72. Goldman D, Lee SC, Casadevall A (1994) Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun 62(11): 4755-4761.
73. Ibrahim AS, Filler SG, Alcouloumre MS, Kozel TR, Edwards JE Jr, et al. (1995) Adherence to and damage of endothelial cells by Cryptococcus neoformans in vitro: role of the capsule. Infect Immun 63(11): 4368-4374.
74. Levitz SM, DiBenedetto DJ (1989) Paradoxical role of capsule in murine bronchoalveolar macrophage-mediated killing of Cryptococcus neoformans. J Immunol 142(2): 659-665.
75. Knaust A, Weber MV, Hammerschmidt S, Bergmann S, Frosch M, et al. (2007) Cytosolic proteins contribute to surface plasminogen recruitment of Neisseria meningitidis. J Bacteriol 189(8): 3246-3255.
76. Kolberg J, Aase A, Bergmann S, Herstad TK, Rodal G, et al. (2006) Streptococcus pneumoniae enolase is important for plasminogen binding despite low abundance of enolase protein on the bacterial cell surface. Microbiology 152(Pt 5): 1307-1317.
77. Rodrigues ML, Nakayasu ES, Oliveira DL, Nimrichter L, Nosanchuk JD, et al. (2008) Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence. Eukaryot Cell 7(1): 58-67.
78. Kakeya H, Udono H, Ikuno N, Yamamoto Y, Mitsutake K, et al. (1997) A 77-kilodalton protein of Cryptococcus neoformans, a member of the heat shock protein 70 family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis. Infect Immun 65(5): 1653-1658.
79. Kakeya H, Udono H, Maesaki S, Sasaki E, Kawamura S, et al. (1999) Heat shock protein 70 (Hsp70) as a major target of the antibody response in patients with pulmonary cryptococcosis. Clin Exp Immunol 115(3): 485-490.
80. Gancedo C, Flores CL (2008) Moonlighting proteins in yeasts. Microbiol Mol Biol Rev 72(1): 197-210.
81. Steen BR, Lian T, Zuyderduyn S, MacDonald WK, Marra M, et al. (2002) Temperature-regulated transcription in the pathogenic fungus Cryptococcus neoformans. Genome Res 12(9): 1386-1400.
82. Angiolella L, Facchin M, Stringaro A, Maras B, Simonetti N, et al. (1996) Identification of a glucan-associated enolase as a main cell wall protein of Candida albicans and an indirect target of lipopeptide antimycotics. J Infect Dis 173(3): 684-690.
83. Eroles P, Sentandreu M, Elorza MV, Sentandreu R (1997) The highly immunogenic enolase and Hsp70p are adventitious Candida albicans cell wall proteins. Microbiology 143 (Pt 2): 313-320.
84. Franklyn KM, Warmington JR (1994) The expression of Candida albicans enolase is not heat shock inducible. FEMS Microbiol Lett 118(3): 219-225.
85. Lai HY, Tam MF, Tang RB, Chou H, Chang CY, et al. (2002) cDNA cloning and immunological characterization of a newly identified enolase allergen from Penicillium citrinum and Aspergillus fumigatus. Int Arch Allergy Immunol 127(3): 181-190.
86. Lopez-Villar E, Monteoliva L, Larsen MR, Sachon E, Shabaz M, et al. (2006) Genetic and proteomic evidences support the localization of yeast enolase in the cell surface. Proteomics 6 (Suppl 1): S107-118.
87. Castillo L, Calvo E, Martinez AI, Ruiz-Herrera J, Valentin E, et al. (2008) A study of the Candida albicans cell wall proteome. Proteomics 8(18): 3871-3881.
88. Jong A, Wu CH, Chen HM, Luo F, Kwon-Chung KJ, et al. (2007) Identification and characterization of CPS1 as a hyaluronic acid synthase contributing to the pathogenesis of Cryptococcus neoformans infection. Eukaryot Cell 6(8): 1486-1496.
89. Jong AY, Stins MF, Huang SH, Chen SH, Kim KS (2001) Traversal of Candida albicans across human blood-brain barrier in vitro. Infect Immun 69(7): 4536-4544.